Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price was down 6.5% during mid-day trading on Tuesday . The company traded as low as $9.83 and last traded at $9.99. Approximately 1,142,401 shares changed hands during mid-day trading, an increase of 37% from the average daily volume of 834,875 shares. The stock had previously closed at $10.68.

Analysts Set New Price Targets

A number of analysts have issued reports on STOK shares. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, HC Wainwright lifted their price objective on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Trading Down 6.0 %

The stock has a market cap of $462.93 million, a P/E ratio of -4.16 and a beta of 0.95. The company has a 50-day moving average price of $10.62 and a two-hundred day moving average price of $12.32.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now owns 51,277 shares of the company’s stock, valued at $618,913.39. This represents a 16.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now directly owns 68,671 shares in the company, valued at $877,615.38. This trade represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock valued at $809,421 in the last quarter. 11.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently made changes to their positions in STOK. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth $63,000. Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth $124,000. Tower Research Capital LLC TRC lifted its holdings in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after buying an additional 4,918 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.